

RECEIVED  
CENTRAL FAX CENTER

MAY 09 2007

Atty's 23208

Pat. App. 10/535,371

CLAIM AMENDMENTS

Claims 1 through 19 (canceled).

1                   Claim 20 (currently amended) Recombinant poxvirus  
2   comprising in the viral genome at least two expression cassettes,  
3   each comprising a cowpox ATI promoter according to SEQ ID NO:1, a  
4   polynucleotide sequence in which not more than 6 nucleotides are  
5   substituted, deleted, and/or inserted into SEQ ID NO:1, said  
6   sequence including nucleotides 25 through 29 of SEQ ID NO:1 and  
7   still active as an ATI promoter, or a polynucleotide comprising at  
8   least 10 nucleotides including nucleotides [[22]] 25 to 29 of SEQ  
9   ID NO: 1 and still active as an ATI promoter and a coding sequence,  
10   wherein the expression of the coding sequence is regulated by said  
11   promoter or said polynucleotides.

1                   Claim 21 (previously presented) Recombinant poxvirus  
2   according to claim 20, wherein the Cowpox ATI promoter has the  
3   biological activity of being active as a Vaccinia virus late  
4   promoter.

Atty's 23208

Pat. App. 10/535,371

1           Claim 22 (previously presented) Recombinant poxvirus  
2   according to claim 20, wherein the Cowpox ATI promoter is SEQ ID  
3   No: 1 or a polynucleotide which comprises at least 10 nucleotides  
4   including nucleotides 22 to 29 of SEQ ID No:1 and still active as  
5   an ATI promoter.

1           Claim 23 (previously presented) Recombinant poxvirus  
2   according to claim 20, wherein the Cowpox ATI promoters in each  
3   expression cassette, in the recombinant poxvirus are identical to  
4   one another.

1           Claim 24 (previously presented) Recombinant poxvirus  
2   according to claim 20, wherein at least two expression cassettes  
3   are inserted into the same insertion site in the poxvirus genome.

1           Claim 25 (previously presented) Recombinant poxvirus  
2   according to claim 20, wherein the Cowpox ATI promoter in at least  
3   one of the expression cassettes has the sequence of SEQ ID.: No. 1.

1           Claim 26 (previously presented) Recombinant poxvirus  
2   according to claim 20, wherein the Cowpox ATI promoter in the  
3   expression cassettes has the sequence of SEQ ID.: No. 1.

Atty's 23208

Pat. App. 10/535,371

1           Claim 27 (previously presented) Recombinant poxvirus  
2 according to claim 20, wherein the poxvirus is selected from the  
3 group consisting of orthopoxviruses and avipoxviruses.

1           Claim 28 (previously presented) Recombinant poxvirus  
2 according to claim 27, wherein the orthopoxvirus is a vaccinia  
3 virus and wherein the avipoxvirus is selected from the group  
4 consisting of canarypoxvirus and fowlpoxvirus.

1           Claim 29 (previously presented) Recombinant poxvirus  
2 according to claim 28, wherein the vaccinia virus is modified  
3 vaccinia virus strain Ankara (MVA), in particular MVA-BN and MVA  
4 575, deposited under numbers V00083008 and V00120707, respectively,  
5 at the European Collection of Animal Cell Cultures (ECACC).

1           Claim 30 (previously presented) Recombinant poxvirus  
2 according to claim 29, wherein at least one of the expression  
3 cassettes is inserted in a naturally occurring deletion site of the  
4 MVA genome with respect to the genome of the vaccinia virus strain  
5 Copenhagen.

1           Claim 31 (previously presented) Recombinant poxvirus  
2 according to claim 20, wherein at least one of the expression  
3 cassettes is inserted in an intergenic region of the poxvirus  
4 genome.

Atty's 23208

Pat. App. 10/535,371

1           **Claim 32 (previously presented) Recombinant poxvirus**  
2   **according to claim 20, wherein at least one of the coding sequences**  
3   **codes for at least one antigen, antigenic epitope, and/or a**  
4   **therapeutic compound.**

**Claim 33 (canceled)**

1           **Claim 34 (previously presented) Vaccine or**  
2   **pharmaceutical composition comprising a recombinant poxvirus**  
3   **according to claim 20.**

**Claim 35 (canceled)**

1           **Claim 36 (previously presented) Method for introducing**  
2   **coding sequences into target cells comprising the infection of the**  
3   **target cells with the virus according to claim 20.**

1           **Claim 37 (previously presented) Method for producing a**  
2   **peptide, protein and/or virus comprising:**  
3           **a) infection of a host cell with the recombinant poxvirus**  
4   **according to claim 20,**  
5           **b) cultivation of the infected host cell under suitable**  
6   **conditions, and**  
7           **c) isolation and/or enrichment of the peptide and/or**  
8   **protein and/or viruses produced by said host cell.**